Navigation Links
Merial to Screen Chimerix' Chemical Library for Animal Health Drug Leads
Date:1/29/2008

DULUTH, Ga. and RESEARCH TRIANGLE PARK, N.C., Jan. 29 /PRNewswire/ -- Merial Limited and Chimerix, Inc. announced today that they have signed an agreement under which Merial will screen a Chimerix chemical library for animal health drug leads. Under the terms of this agreement, Merial has an option to negotiate a license with Chimerix for leads identified for possible animal health use.

"This collaboration with Chimerix provides us with an opportunity to further expand our ability to identify novel active compounds that will form the basis of new products designed to meet our customers' future needs," states Dr. Peter Hanson, Head of Pharmaceutical R&D.

"Collaborating with Merial, a known leader in animal health, will allow us to capitalize on active leads obtained through our chemical library for animal health indications that otherwise may not be developed," stated George Painter, President and CEO of Chimerix. "Our company is excited about the possibility of contributing to the development of a medication that will positively impact the health and well-being of animals."

About Merial

Merial is a world-leading, innovation-driven animal health company, providing a comprehensive range of products to enhance the health, well-being and performance of a wide range of animals. Merial employs more than 5,000 people and operates in more than 150 countries worldwide. Its 2007 sales were nearly $2.5 billion. Merial Limited is a joint venture between Merck & Co., Inc. and sanofi-aventis. For more information, please see http://www.merial.com.

About Chimerix

Chimerix, Inc. discovers, develops and commercializes therapeutics with enhanced pharmaceutical properties that are active against a broad range of viral diseases. Leveraging a powerful lipid, prodrug technology, ProLipTag(TM), Chimerix is able to develop drug candidates with oral-availability, increased potency and targeted delivery. These enhanced pharmaceutical properties can be applied to new drug moieties or known drugs to improve dosing parameters, broaden therapeutic applications and decrease the risk of adverse events. For more information, please see http://www.chimerix-inc.com.


'/>"/>
SOURCE Chimerix, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. NeoMatrix Announces Additional Funding for Breakthrough Breast Cancer Screening Test
2. AGI Dermatics President to be Keynote Speaker at the 11th Annual Sunscreen Symposium
3. BioReliance Launches Next-Generation Genotoxicity Screening Service
4. Diamics Receives European CE Mark Approval for Its Pap-Map(TM) System for Cervical Cancer Screening
5. Enigma Diagnostics to Develop Clinical Diagnostics Platform for UK National Chlamydia Screening Programme
6. Swiss Experts Recommend QuantiFERON(R)-TB Gold for Tuberculosis Infection Screening Prior to Initiating anti-TNF-a Therapy
7. Dude, big screen TVs, flexible electronics and surfboards made from same new material!
8. FED-TVs with carbon nanotube technology could supersede plasma and LCD flat screens
9. Siemens Unveils New Digital Mammography System for Optimized Screening
10. International Association of Fire Fighters (IAFF) Advocates Screening Fire Fighters for Carbon Monoxide Poisoning Using Pulse CO-Oximetry
11. Abbott Announces Approval of First Fully Automated Blood Screening Test for HTLV-I/HTLV-II
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016   EpiBiome , a precision microbiome ... in debt financing from Silicon Valley Bank (SVB). The ... to advance its drug development efforts, as well as ... "SVB has been an incredible strategic partner to ... traditional bank would provide," said Dr. Aeron Tynes ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the ... Convention Center and will showcase its product’s latest features from June 26 to ... a scientific poster on Disrupting Clinical Trials in The Cloud during the conference. ...
(Date:6/23/2016)... , June 23, 2016 ... research report to its pharmaceuticals section with historic ... details and much more. Complete report ... 151 pages, profiling 15 companies and supported with ... http://www.reportsnreports.com/reports/601420-global-cell-culture-media-industry-2016-market-research-report.html . The Global ...
Breaking Biology Technology:
(Date:4/13/2016)... April 13, 2016  IMPOWER physicians supporting Medicaid patients ... a new clinical standard in telehealth thanks to a ... the higi platform, IMPOWER patients can routinely track key ... body mass index, and, when they opt in, share ... visit to a local retail location at no cost. ...
(Date:3/31/2016)... -- Genomics firm Nabsys has completed a financial  restructuring under ... M.D., who returned to the company in October 2015. ... including Chief Technology Officer, John Oliver , Ph.D., ... Vice President of Software and Informatics, Michael Kaiser ... Bready served as CEO of Nabsys from 2005-2014 and ...
(Date:3/23/2016)... , March 23, 2016 ... Interesse erhöhter Sicherheit Gesichts- und Stimmerkennung mit ... Inc. (NASDAQ: MESG ), ein ... dass das Unternehmen mit SpeechPro zusammenarbeitet, um ... der Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im ...
Breaking Biology News(10 mins):